Vita Biotech Retains CBIH Services for Clinical Studies

Rhea-AI Summary

Vita Biotech has partnered with Cannabis Bioscience International Holdings (OTC Pink: CBIH) to fund CBIH's clinical studies. This alliance will expedite CBIH's data collection for evaluating their formulations' efficacy and safety, facilitating the company's scientific and commercial objectives. The partnership involves Vita Biotech acting as a financial subsidiary, aiding in streamlined financing, and risk management by isolating each medical formulation into a unique legal entity. Texas has been chosen for patent housing due to its favorable business environment. Both companies maintain ethical standards and prioritize data integrity, aiming to enhance patient care and credibility in medical cannabis research.

Positive

• Vita Biotech's funding will accelerate CBIH's clinical data collection and research.
• The partnership supports CBIH's scientific and commercial goals, boosting progress.
• The risk management strategy isolates each medical formulation into a unique legal entity, simplifying financing.
• Choice of Texas for patent housing offers favorable judicial precedents, cost-effective litigation, and access to adept federal courts.
• Partnership enhances credibility among leading pharmaceutical companies.

Negative

• Potential legal challenges still exist despite the defensive posture.
• There may be risks associated with isolating each formulation into a unique legal entity, including complexities in management and operations.
• The success of the strategy heavily relies on maintaining ethical standards and data integrity, which could be challenging.

Houston, Texas--(Newsfile Corp. - June 5, 2024) - Vita Biotech Research has entered into a significant partnership with Cannabis Bioscience International Holdings (OTC Pink: CBIH), to fund the clinical data collection efforts of CBIH's rigorous data clinical studies, underscoring Vita Biotech's commitment to supporting cutting-edge research and ensuring the highest standards of clinical data integrity.

Through this strategic alliance, Vita Biotech will act as a financial subsidiary and catalyst for CBIH's data collection trials, a vital phase in evaluating the efficacy and safety of its formulations before they reach the market. This accelerated funding is expected to speed up CBIH's progress toward its scientific and commercial goals.

Furthermore, this collaboration allows CBIH to chart a course of its reconstruction process as it facilitates to isolate each medical formulation into a unique legal entity. This risk management strategy aligns with industry practices aimed at simplifying financing and partnerships, streamlining intellectual property and licensing processes.

The choice of Texas as the jurisdiction for patent housing is driven by its business-friendly environment, including favorable judicial precedents, cost-effective litigation, and access to federal courts adept in handling complex cases. Therefore, this calculated maneuver would place CBIH in a strong defensive posture in the event of legal challenges, and it is foreseen to lessen potential legal liabilities of the parent corporation.

The decision to proceed with this collaboration followed medical legal standards to mitigate any potential medical conflicts arising from the studies, upholding ethical standards to maintain credibility and executing CBIH's protocols effectively, which could lead to improved statistical significance.

"The nature of clinical trials and data collection necessitates a cooperative endeavor between different entities, each bringing unique advantages to the table, without compromising the integrity and safety of data management during the trials. This way we take a significant leap forward in both organizations' missions and the enhancement of patient care," says Dr. Jennifer Salguero, PhD in Science specialized in Microbiology from São Paulo Brazil University, and VITA's Director of Clinical Trial Operations.

Overall, this partnership offers a platform for funding CBIH's projects, safeguards both parties from risks related to intellectual property and litigation, and ensures the meticulous and ethical collection of data. CBIH and Vita Biotech look forward to potentially bolster the credibility of our research among leading pharmaceutical companies, paving the way as pioneers in medical cannabis clinical research.

FORWARD-LOOKING STATEMENTS

This press release may contain forward-looking statements. The words "believe," "expect," "should," "intend," "estimate," "projects," variations of such words and similar expressions identify forward-looking statements, but their absence does not mean that a statement is not a forward-looking statement. These forward-looking statements are based upon the Company's current expectations and are subject to a number of risks, uncertainties, and assumptions. The Company undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events, or otherwise. Among the important factors that could cause actual results to differ significantly from those expressed or implied by such forward-looking statements are risks that are detailed in the Company's filings, which are on file at www.OTCmarkets.com.

For more information contact us at:
(214) 733-0868
ir@cbih.net
Dante Picazo
CEO - CBIH
Website: www.cbih.net
X: www.twitter.com/cbihstock
Instagram: www.instagram.com/CBIHSTOCK

Investor Relations:
East Coast
Peter Nicosia
Bull in Advantage, LLC
Phone: 585-703-6565
Email: Info@BlueHorseshoeStocks.com

West Coast
Zach Logan
Pacific Capital Markets LLC
Phone: 858.864.0011
Email: pacificcapitalmarketsllc@gmail.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/211751

FAQ

What is the partnership between Vita Biotech and CBIH about?

The partnership involves Vita Biotech funding CBIH's clinical data collection efforts to expedite research on the efficacy and safety of CBIH's formulations.

How will the Vita Biotech and CBIH partnership affect CBIH's stock (CBIH)?

The partnership is expected to enhance CBIH's research credibility and progress towards its scientific and commercial goals, potentially impacting the stock positively.

What are the benefits of choosing Texas for patent housing?

Texas offers a favorable business environment, including judicial precedents, cost-effective litigation, and adept federal courts, which benefit patent housing.

Why is isolating each medical formulation into a unique legal entity beneficial for CBIH?

Isolating each formulation simplifies financing and partnerships, streamlines intellectual property and licensing processes, and mitigates potential legal liabilities.

What ethical standards are being upheld in the Vita Biotech and CBIH partnership?

The partnership follows medical legal standards to mitigate conflicts and maintain data integrity and credibility in clinical trials.